The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease

References

• Sydentricker V, Mulherin W, Houseal R. Sickle cell anemia: report of two cases in children with necropsy in one case. Am. J. Dis. Child.26, 132–154 (1923).
   Google Scholar
• Obama MT, Dongmo L, Nkemayim C, Mbede J, Hagbe P. Stroke in children in Yaounde, Cameroon. Indian Pediatr.31(7), 791–795 (1994).
   PubMedGoogle Scholar
• Ohene-Frempong K, Weiner SJ, Sleeper LA et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood91(1), 288–294 (1998).
   PubMed Web of Science ®Google Scholar
• Powars D, Wilson B, Imbus C, Pegelow C, Allen J. The natural history of stroke in sickle cell disease. Am. J. Med.65(3), 461–471 (1978).
   PubMed Web of Science ®Google Scholar
• Kissela B, Schneider A, Kleindorfer D et al. Stroke in a biracial population: the excess burden of stroke among blacks. Stroke35(2), 426–431 (2004).
   PubMed Web of Science ®Google Scholar
• Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore)84(6), 363–376 (2005).
   PubMed Web of Science ®Google Scholar
• Strouse JJ, Jordan LC, Lanzkron S, Casella JF. The excess burden of stroke in hospitalized adults with sickle cell disease. Am. J. Hematol.84(9), 548–552 (2009).
   PubMed Web of Science ®Google Scholar
• Njamnshi AK, Mbong EN, Wonkam A et al. The epidemiology of stroke in sickle cell patients in Yaounde, Cameroon. J. Neurol. Sci.250(1–2), 79–84 (2006).
   PubMedGoogle Scholar
• Kehinde MO, Temiye EO, Danesi MA. Neurological complications of sickle cell anemia in Nigerian Africans – a case–control study. J. Natl Med. Assoc.100(4), 394–399 (2008).
   PubMed Web of Science ®Google Scholar
• Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. J. Pediatr.120(3), 360–366 (1992).
   PubMed Web of Science ®Google Scholar
• Jacobs BS, Boden-Albala B, Lin I-F, Sacco RL. Stroke in the young in the Northern Manhattan Stroke Study. Stroke33(12), 2789–2793 (2002).
   PubMed Web of Science ®Google Scholar
• Strouse JJ, Hulbert ML, Debaun MR, Jordan LC, Casella JF. Primary hemorrhagic stroke in children with sickle cell disease is associated with recent transfusion and use of corticosteroids. Pediatrics118(5), 1916–1924 (2006).
   PubMed Web of Science ®Google Scholar
• Pegelow CH, Colangelo L, Steinberg M et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Am. J. Med.102(2), 171–177 (1997).
   PubMed Web of Science ®Google Scholar
• Wierenga KJ, Serjeant BE, Serjeant GR. Cerebrovascular complications and parvovirus infection in homozygous sickle cell disease. J. Pediatr.139(3), 438–442 (2001).
   PubMed Web of Science ®Google Scholar
• Scothorn DJ, Price C, Schwartz D et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J. Pediatr.140(3), 348–354 (2002).
   PubMed Web of Science ®Google Scholar
• Dobson SR, Holden KR, Nietert PJ et al. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood99(9), 3144–3150 (2002).
   PubMed Web of Science ®Google Scholar
• Strouse JJ, Field J, Crawford RD, Lanzkron S. Antecedent transfusion and primary hemorrhagic stroke in adults with sickle cell disease. ASH Annual Meeting Abstracts112(11), 1437 (2008).
   Google Scholar
• Sebastiani P, Ramoni MF, Nolan V, Baldwin CT, Steinberg MH. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat. Genet.37(4), 435–440 (2005).
   PubMed Web of Science ®Google Scholar
• Adams R, Mckie V, Nichols F et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N. Engl. J. Med.326(9), 605–610 (1992).
   PubMed Web of Science ®Google Scholar
• Adams RJ, Mckie VC, Hsu L et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N. Engl. J. Med.339(1), 5–11 (1998).
   PubMed Web of Science ®Google Scholar
• Silva G, Vicari P, Figueiredo M, Junior H, Idagawa M, Massaro A. Migraine-mimicking headache and sickle cell disease: a transcranial Doppler study. Cephalalgia26(6), 678–683 (2006).
   PubMed Web of Science ®Google Scholar
• Valadi N, Silva GS, Bowman LS et al. Transcranial Doppler ultrasonography in adults with sickle cell disease. Neurology67(4), 572–574 (2006).
   PubMedGoogle Scholar
• Silva GS, Vicari P, Figueiredo MS, Junior HC, Idagawa MH, Massaro AR. Brain magnetic resonance imaging abnormalities in adult patients with sickle cell disease correlation with transcranial doppler findings. Stroke40(7), 2408–2412 (2009).
   PubMedGoogle Scholar
• Latchaw RE, Alberts MJ, Lev MH et al. Recommendations for imaging of acute ischemic stroke. Stroke40(11), 3646–3678 (2009).
   PubMed Web of Science ®Google Scholar
• Deane CR, Goss D, Bartram J et al. Extracranial internal carotid arterial disease in children with sickle cell anemia. Haematologica95(8), 1287–1292 (2010).
   PubMedGoogle Scholar
• Jordan LC, Strouse JJ. Will submandibular TCD prevent stroke in children with sickle cell anemia? Neurology73(5), 340–341 (2009).
   PubMedGoogle Scholar
• Brott TG, Halperin JL, Abbara S et al.; ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS. Guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery developed in collaboration with the American Academy of Neurology and Society of Cardiovascular Computed Tomography. J. Am. Coll. Cardiol.57(8), 1002–1044 (2011).
   PubMed Web of Science ®Google Scholar
• Banna M. Post-angiographic blindness in a patient with sickle cell disease. Invest. Radiol.27(2), 179–181 (1992).
   PubMedGoogle Scholar
• Stockman JA, Nigro MA, Mishkin MM, Oski FA. Occlusion of large cerebral vessels in sickle-cell anemia. N. Engl. J. Med.287(17), 846–849 (1972).
   PubMed Web of Science ®Google Scholar
• Oyesiku NM, Barrow DL, Eckman JR, Tindall SC, Colohan AR. Intracranial aneurysms in sickle-cell anemia: clinical features and pathogenesis. J. Neurosurg.75(3), 356–363 (1991).
   PubMed Web of Science ®Google Scholar
• Furie KL, Kasner SE, Adams RJ et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke42(1), 227–276 (2011).
   PubMed Web of Science ®Google Scholar
• Vicari P, Sampaio Silva G, De Cassia Rosario Cavalheiro R, Massaro AR, Figueiredo MS. Fulminant stroke in an adult patient with sickle cell anemia. Acta Haematol.116(1), 67–69 (2006).
   PubMedGoogle Scholar
• Jayabose S, Sheikh F, Mitra N. Exchange transfusion in the management of CNS crisis in sickle cell disease. Clin. Pediatr (Phila.)22(11), 776–777 (1983).
   PubMedGoogle Scholar
• Huttenlocher PR, Moohr JW, Johns L, Brown FD. Cerebral blood flow in sickle cell cerebrovascular disease. Pediatrics73(5), 615–621 (1984).
   PubMedGoogle Scholar
• Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke. Stroke40(7), 2438–2441 (2009).
   PubMed Web of Science ®Google Scholar
• Adams HP Jr, Del Zoppo G, Alberts MJ et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation115(20), e478–e534 (2007).
   PubMed Web of Science ®Google Scholar
• Gilligan AK, Thrift AG, Sturm JW, Dewey HM, Macdonell RA, Donnan GA. Stroke units, tissue plasminogen activator, aspirin and neuroprotection: which stroke intervention could provide the greatest community benefit? Cerebrovasc. Dis.20(4), 239–244 (2005).
   PubMedGoogle Scholar
• Stroke Unit Trialists’ Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst. Rev.4, CD000197 (2007).
   PubMedGoogle Scholar
• Charneski L, Congdon HB. Effects of antiplatelet and anticoagulant medications on the vasoocclusive and thrombotic complications of sickle cell disease: a review of the literature. Am. J. Health Syst. Pharm.67(11), 895–900 (2010).
   PubMedGoogle Scholar
• Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am. Heart J.162(1), 115–124.e2 (2011).
   PubMed Web of Science ®Google Scholar
• Powars D, Adams RJ, Nichols FT, Milner P, Charache S, Sarnaik S. Delayed intracranial hemorrhage following cerebral infarction in sickle cell anemia. J. Assoc. Acad. Minor Phys.1(3), 79–82 (1990).
   PubMedGoogle Scholar
• Willey JZ, Elkind MSV. Stroke: do statins improve outcomes after acute ischemic stroke? Nat. Rev. Neurol.7(7), 364–365 (2011).
   PubMedGoogle Scholar
• Hoppe C, Kuypers F, Larkin S, Hagar W, Vichinsky E, Styles L. A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br. J. Haematol.153(5), 655–663 (2011).
   PubMed Web of Science ®Google Scholar
• Sarnaik S, Soorya D, Kim J, Ravindranath Y, Lusher J. Periodic transfusions for sickle cell anemia and CNS infarction. Am. J. Dis. Child.133(12), 1254–1257 (1979).
   PubMedGoogle Scholar
• Wilimas J, Goff JR, Anderson HR Jr, Langston JW, Thompson E. Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents. J. Pediatr.96(2), 205–208 (1980).
   PubMed Web of Science ®Google Scholar
• Wang WC, Kovnar EH, Tonkin IL et al. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J. Pediatr.118(3), 377–382 (1991).
   PubMed Web of Science ®Google Scholar
• Rana S, Houston PE, Surana N, Shalaby-Rana EI, Castro OL. Discontinuation of long-term transfusion therapy in patients with sickle cell disease and stroke. J. Pediatr.131(5), 757–760 (1997).
   PubMedGoogle Scholar
• Hulbert ML, Mckinstry RC, Lacey JL et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood117(3), 772–779 (2011).
   PubMed Web of Science ®Google Scholar
• Greenway A, Ware RE, Thornburg CD. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. Am. J. Hematol.86(4), 357–361 (2011).
   PubMedGoogle Scholar
• Ware RE, Helms RW. Stroke with transfusions Changing to Hydroxyurea (SWiTCH): a Phase 3 randomized clinical trial for treatment of children with sickle cell anemia, previous stroke, and iron overload. ASH Annual Meeting Abstracts116(21), 844 (2010).
   Google Scholar
• Ali SB, Moosang M, King L, Knight-Madden J, Reid M. Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke. Am. J. Hematol.86(10), 846–850 (2011).
   PubMedGoogle Scholar
• Walters MC, Hardy K, Edwards S et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol. Blood Marrow Transplant.16(2), 263–272 (2010).
   PubMed Web of Science ®Google Scholar
• Woodard P, Helton KJ, Khan RB et al. Brain parenchymal damage after haematopoietic stem cell transplantation for severe sickle cell disease. Br. J. Haematol.129(4), 550–552 (2005).
   PubMed Web of Science ®Google Scholar
• Hsieh MM, Kang EM, Fitzhugh CD et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N. Engl. J. Med.361(24), 2309–2317 (2009).
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Luznik L, Bolanos-Meade J, Leffell MS, Jones RJ, Fuchs EJ. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant42(8), 523–527 (2008).
   PubMed Web of Science ®Google Scholar
• Fryer RH, Anderson RC, Chiriboga CA, Feldstein NA. Sickle cell anemia with moyamoya disease: outcomes after EDAS procedure. Pediatr. Neurol.29(2), 124–130 (2003).
   PubMed Web of Science ®Google Scholar
• Hankinson TC, Bohman LE, Heyer G et al. Surgical treatment of moyamoya syndrome in patients with sickle cell anemia: outcome following encephaloduroarteriosynangiosis. J. Neurosurg. Pediatr.1(3), 211–216 (2008).
   PubMed Web of Science ®Google Scholar
• Smith ER, Mcclain CD, Heeney M, Scott RM. Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia: perioperative management and surgical outcome. Neurosurg. Focus26(4), E10 (2009).
   PubMed Web of Science ®Google Scholar
• Mendelow AD, Gregson BA, Fernandes HM et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet365(9457), 387–397 (2005).
   PubMed Web of Science ®Google Scholar
• Morgenstern LB, Hemphill JC 3rd, Anderson C et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke41(9), 2108–2129 (2010).
   PubMed Web of Science ®Google Scholar
• Bederson JB, Connolly ES, Batjer HH et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke40(3), 994–1025 (2009).
   PubMed Web of Science ®Google Scholar
• Mcconachie NS, Jaspan T, Hatrick AG et al. Complications of sickle cell disease: Intracranial aneurysms and their treatment. Clin. Radiol.53(5), 388–389 (1998).
   PubMedGoogle Scholar
• King AA, White DA, Mckinstry RC, Noetzel M, Debaun MR. A pilot randomized education rehabilitation trial is feasible in sickle cell and strokes. Neurology68(23), 2008–2011 (2007).
   PubMed Web of Science ®Google Scholar
• Langhorne P, Bernhardt J, Kwakkel G. Stroke rehabilitation. Lancet377(9778), 1693–1702 (2011).
   PubMed Web of Science ®Google Scholar
• Wang W, Enos L, Gallagher D et al. Neuropsychologic performance in school-aged children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. J. Pediatr.139(3), 391–397 (2001).
   PubMed Web of Science ®Google Scholar
• Houston PE, Rana S, Sekhsaria S, Perlin E, Kim KS, Castro OL. Homocysteine in sickle cell disease: relationship to stroke. Am. J. Med.103(3), 192–196 (1997).
   PubMed Web of Science ®Google Scholar
• Miller ST, Macklin EA, Pegelow CH et al. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J. Pediatr.139(3), 385–390 (2001).
   PubMed Web of Science ®Google Scholar
• Kirkham FJ, Hewes DK, Prengler M, Wade A, Lane R, Evans JP. Nocturnal hypoxaemia and central-nervous-system events in sickle-cell disease. Lancet357(9269), 1656–1659 (2001).
   PubMed Web of Science ®Google Scholar
• Adams RJ, Mckie VC, Carl EM et al. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann. Neurol.42(5), 699–704 (1997).
   PubMed Web of Science ®Google Scholar
• Kwiatkowski JL, Granger S, Brambilla DJ, Brown RC, Miller ST, Adams RJ. Elevated blood flow velocity in the anterior cerebral artery and stroke risk in sickle cell disease: extended analysis from the STOP trial. Br. J. Haematol.134(3), 333–339 (2006).
   PubMedGoogle Scholar
• Flanagan JM, Frohlich DM, Howard TA et al. Genetic predictors for stroke in children with sickle cell anemia. Blood117(24), 6681–6684 (2011).
   PubMed Web of Science ®Google Scholar
• Adams RJ, Kutlar A, Mckie V et al. Alpha thalassemia and stroke risk in sickle cell anemia. Am. J. Hematol.45(4), 279–282 (1994).
   PubMed Web of Science ®Google Scholar
• Hoppe C, Klitz W, Cheng S et al. Gene interactions and stroke risk in children with sickle cell anemia. Blood103(6), 2391–2396 (2004).
   PubMed Web of Science ®Google Scholar
• Taylor JGT, Tang DC, Savage SA et al. Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood100(13), 4303–4309 (2002).
   PubMed Web of Science ®Google Scholar
• Tang DC, Prauner R, Liu W et al. Polymorphisms within the angiotensinogen gene (GT-repeat) and the risk of stroke in pediatric patients with sickle cell disease: a case–control study. Am. J. Hematol.68(3), 164–169 (2001).
   PubMed Web of Science ®Google Scholar
• Romana M, Diara JP, Doumbo L et al. Angiotensinogen gene associated polymorphisms and risk of stroke in sickle cell anemia: additional data supporting an association. Am. J. Hematol.76(3), 310–311 (2004).
   PubMedGoogle Scholar